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INTEGRATING HEALTH ECONOMICS INTO THE 
PRODUCT DECISION- MAKING PROCESS: 
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OBJECTIVE: The purpose of this study was to under-
stand the decision-making process used when selecting
ulcer-dressing products, and to ascertain the use of health
economics in the decision process.
METHODS: Diverse groups of nurses highly involved in
product selection were interviewed. The groups included
five home-care nurses (Group 1), four acute-care nurses
(Group 2), and five nurses who spent some time in LTC
(Group 3). Discussions centered on 1) product switching
triggering events, 2) key decision-makers, 3) mapping the
decision-making process, and 4) understanding of health
economics. Information about the key decision-makers at
different institutions was discussed.
RESULTS: 1) Performance issues were the most common
reasons for product switching (66%). Product availabil-
ity was the most influential factor (48%). 2) No differ-
ences in product selection criteria were observed among
nurses in home, acute and long-term care. However, level
and role of the nurse in each setting influenced his or her
part in decision-making and product selection. 3) Product
evaluation and hands-on experience were the most im-
portant elements for selecting a new or replacement
product. The ability to incorporate the product into cus-
tomized patient protocols was also important. 4) While
nurses were somewhat familiar with the term “cost-effec-
tiveness,” most preferred the term “value.” Approxi-
mately half used such information to support wound-care
product decisions. Nurses were more likely to consider a
product supported by a straightforward economic assess-
ment rather than a complex decision analysis.
CONCLUSION: Product selection relies heavily on trial
evaluations. In addition, published health-economic stud-
ies are often too complicated. In order for health-eco-
nomics research to inform decision-making in the wound-
care market, studies should: 1) identify target audiences
and address their decision-making needs; 2) “speak” to
their audience by using terms familiar to decision-mak-
ers; and 3) present simplified diagrams, charts or models.
 
PHP2
 
GASTROINTESTINAL DRUG POLICY, DRUG 
SELECTION AND RESOURCE UTILIZATION— A 
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OBJECTIVE:
 
 Canadian provinces have different policies
on the reimbursement of proton pump inhibitors (PPIs)
(Quebec open, Ontario restricted). This study examined
the effect of these policies on the use of PPI and H2-recep-
tor antagonists (H2RA), one-year gastrointestinal (GI) re-
source utilization and costs.
METHODS: Merged provincial databases from Quebec
and Ontario were analyzed for new users of PPIs and
H2RAs aged 66 or greater who began treatment between
November 1, 1996 to October 31, 1997. GI related ser-
vices and costs (GI drugs, physician visits, GI procedures
and hospitalizations) were analyzed using multivariate
regression equations on an intent-to-treat basis.
RESULTS: 82,314 Ontario and 19,719 (50% sample)
Quebec patients were identified as new GI drug users.
The patients were similar in age, gender and length of fol-
low-up. At the initial visit, 12.5% of Ontario and 24.1%
of Quebec patients were prescribed PPIs, and 63.7% of
Ontario and 50.0% of Quebec patients were prescribed
H2RAs. GI hospitalization occurred in 1.7% of Ontario
and 1.4% of Quebec patients (p  .01). Endoscopy rate
for Ontario was 4.7% and 9.1% for Quebec (p  .001);
upper GI radiography rate was 13.8% for Ontario and
9.9% for Quebec (p  .01). Factors related to PPI versus
H2RA prescription included residence in Quebec (OR
2.3), initial prescription by GI specialist (OR 4.1), other
specialist (OR 1.9) and endoscopy (OR 1.9).
CONCLUSION: Restrictive drug policy influenced both
drug and other resource utilization. In both provinces,
PPI use was associated with increased disease severity
and resource utilization.
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OBJECTIVES:
 
 To develop a macro-economic model to
assist European policy makers in assessing the effects of
different measures to reduce problematic drug use.
METHODS: Existing economic behavior theories and
different modalities of heroin use provided a number of
principles and a framework out of which a cohort-level
macro-economic model was created. A 20-year, Markov
state-transition model was developed, within which a
(potential) cohort of the adult general population makes
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transitions from one state to another within discrete time
frames (6 months). The states were: non-user; has sam-
pled (has tried); non-dependent user; ex-user; dependent-
not treated; dependent-treated; abstinent; death. The av-
erage quantity of heroin demanded was determined at the
cohort level, based on published price and income elastic-
ities. Scenario-analyses showed the impact of variations
in different parameters and the effects of different policy
measures on the results. Using a bottom-up approach, the
results were then aggregated to a population level.
RESULTS: Calculating the 20-year demand for heroin on
a cohort level generated an average demand between
5.96g to 20.45g per European citizen, depending on dif-
ferent variables in the model. Sub-analyses showed that a
50% increase in the price level of heroin could have a
negative impact of 72% on total heroin demand. A de-
crease in sampling of 50% generated an almost equal im-
pact on total heroin demand. Analyzing the impact of
substitution treatment indicated that easier access to
treatment and a longer follow-up after completing treat-
ment would have a greater impact than the success of
treatment itself in achieving abstinence.
CONCLUSIONS: This is the first macro-economic model
designed for policy makers to assess the impact of mea-
sures to control problematic drug use. Measures aimed at
preventing a first heroin dose and controlling the price of
heroin seem to be worth focussing on.
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OBJECTIVE:
 
 To develop criteria for testing the validity
of indicators of prescribing cost, efficiency or quality.
 
METHODS:
 
 Our methodology was based on techniques
used to validate psychological tests. Face validity was
used to test the construct of the prescribing indicator (i.e.
what is it trying to measure?). Two tests of external va-
lidity were used to relate the performance of each indica-
tor to other measures of the same construct (concurrent
validity and predictive validity). In addition we used a
published method to test the robustness of ranking of
General Practices by each prescribing indicator. We ob-
tained data for all 78 General Practices in Tayside for the
years 1993-97.
RESULTS: We identified five prescribing indicators that
had been previously tested for face validity in a two-stage
Delphi consultation study. These were: 1) the ratio of
bendrofluazide 2.5mg to total bendrofluazide items; 2)
the ratio of generic items to all items; 3) the ratio of tri-
methoprim to trimethoprim/sulphamethoxazole; 4) the
ratio of antibiotics from the primary-care formulary to
all antibiotics; and, 5) the ratio of maintenance dose of
proton pump inhibitors to all PPI items. Crude ranking of
general practices compared well with the results of the
more robust rankings generated by the Marshall and
Spiegelhalter ranking. There were significant improve-
ments in the achievement of all five indicators by Tayside
practices from 1993 to 1997, and ranking of each prac-
tice was robust over time. However, there was no rela-
tionship between an individual practice’s ranking by dif-
ferent indicators.
CONCLUSIONS: Differences between practices are sta-
tistically robust and practices have shown significant
improvements in all indicators over time. However, the
absence of concurrent validity between indicators casts
doubt on their use as measures of general prescribing
quality.
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OBJECTIVES:
 
 We use the Chronic Disease Score meth-
odology to estimate the prevalence of a number of
chronic conditions in the Republic of Ireland from rou-
tinely available prescribing data, which we then compare
with epidemiological estimates.
METHODS: Using automated outpatient pharmacy data,
measures of chronic disease severity called Chronic Dis-
ease Scores were constructed. We use these to measure
disease prevalence. Since many drugs have multiple indi-
cations, incidental users and the chronically ill must be
distinguished. Any person receiving four or more pre-
scriptions within a 12-month period for a chronic disease
category is identified as suffering from that chronic dis-
ease. Prevalence estimates are compared with estimates
for these conditions based on a review of the epidemiol-
ogy literature. Data refer to the General Medical Services
(GMS) scheme in Ireland. The GMS provides free pri-
mary care to those on low income and to other hardship
cases, covering approximately 31% of the Irish popula-
tion. Data on drugs prescribed to all individuals on the
GMS scheme in four health board areas were collected
for the period from September 1999 to August 2000, rep-
resenting a total of 415,271 people or approximately
37% of the GMS population.
RESULTS: Estimates of prevalence based on the Chronic
Disease Score are similar to epidemiological estimates.
This is especially true for conditions such as diabetes, ep-
ilepsy and asthma, and less so for depression and other
mental illness, where under-diagnosis is commonplace.
CONCLUSIONS: The results suggest that prescribing data
is a rich source of information on morbidity in the com-
munity. It is locally sensitive, timely and cheap to collect.
As long as certain caveats are applied, this type of infor-
mation has many uses in the surveillance of the public’s
health.
